Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:company
|
| gptkbp:CEO |
gptkb:Douglas_S._Ingram
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focusesOn |
gptkb:Duchenne_muscular_dystrophy
rare diseases genetic medicine |
| gptkbp:foundedYear |
1980
|
| gptkbp:fullName |
Sarepta Therapeutics, Inc.
|
| gptkbp:headquartersLocation |
gptkb:Cambridge,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
SRPT
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:listedOn |
gptkb:NASDAQ
|
| gptkbp:notableProduct |
gptkb:Amondys_45
gptkb:Elevidys gptkb:Exondys_51 gptkb:Vyondys_53 |
| gptkbp:numberOfEmployees |
over 900
|
| gptkbp:stockSymbol |
gptkb:SRPT
|
| gptkbp:tradedOn |
gptkb:SRPT
|
| gptkbp:website |
https://www.sarepta.com/
|
| gptkbp:bfsParent |
gptkb:Sarepta_Therapeutics
|
| gptkbp:bfsLayer |
7
|